Matrix metalloproteinase (MMP) 9 is associated with clinical parameters of severity in cystic fibrosis (CF) Source: Annual Congress 2010 - Cystic fibrosis: lung disease and much more Year: 2010
Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs) and transforming growth factor-β (TGFβ) expression in small airways (SA) of usual idiopathic pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hip Source: Annual Congress 2007 - Role of genomics and biological tools in the work-up of interstitial lung disease Year: 2007
Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007
Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis Source: Eur Respir J 2015; 46: 384-394 Year: 2015
The role of matrix metalloproteinases in cystic fibrosis lung disease Source: Eur Respir J 2011; 38: 721-727 Year: 2011
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Matrix metalloproteinase 2 expression in distal lung of fatal asthma Source: Eur Respir J 2006; 28: Suppl. 50, 549s Year: 2006
Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002
Matrix Metalloproteinases (MMPs) in patients with pulmonary tuberculosis (PT) and comorbid COPD Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Matrix metalloproteinases in pulmonary fibrosis Source: Annual Congress 2013 –Regulation of lung inflammation and repair by proteolysis Year: 2013
MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008
Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo Source: Eur Respir J 2002; 20: 170-176 Year: 2002
Fine mapping of matrix metalloproteinase 16 (MMP16) gene: Validation of a significant association with bronchopulmonary dysplasia (BPD) Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010
Effect of recombinant α-1 antitrypsin (rAAT) and TAPI on neutrophil elastase (NE) and matrix metalloproteinase-9 (MMP9) activity in induced sputum (IS) from healthy smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Metalloproteinases in idiopathic pulmonary fibrosis Source: Eur Respir J 2011; 38: 1461-1467 Year: 2011